References
- Zangari M, Saghafifar F, Mehta P, et al. The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost 2003; 29: 275–281
- Rajkumar V, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated bye the eastern cooperative oncology group. J Clin Oncol 2006; 24: 431–436
- Camba L, Peccatori J, Pescarollo A, Tresoldi M, Corradini P, Bregni M. Thalidomide and thrombosis in patients with multiple myeloma. Haematologica 2001; 86: 1108–1109
- Osman K, Comenzo R, Rajkumar S V. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 2001; 344: 1951–1952
- Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, Cangialosi C, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet 2006; 367: 825–831
- Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16–19
- Niesvizky R, Martinez-Banos D, Jalbrzikowski J, Christos P, Furst J, De Sancho M, Mark T, et al. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leuk Lymphoma 2007; 48: 2330–2337
- Palumbo A, Rajkumar S V, Dimopoulous M A, Richardson P G, San Miguel J, Barlogie B, Harousseau J, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22: 414–423
- Palumbo A, Facon T, Sonneveld P, Blade J, Offidani M, Gay F, Moreau P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008; 111: 3968–3977